New lupus drug candidate enters human trials
NCT ID NCT07538154
First seen Apr 23, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tests a new drug, SCTC21C, in 159 adults with systemic lupus erythematosus (SLE). The goal is to see if it is safe and can help control the disease. Participants must have moderate to severe lupus and be on standard treatments. The study is in two parts: first checking safety, then measuring how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.